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Abstract 
Immune checkpoint blockade therapy by targeting the programmed death protein 1/programmed death ligand 
1 (PD-L1) axis using antibodies has yielded promising clinical responses in patients with non-small cell lung cancer 
(NSCLC). However, owing to the dynamic expression of PD-L1, degree of mutational/neoantigen load, intratumoral 
heterogeneity, infiltrated immune cells of tumor microenvironment of NSCLC, the response rates to these agents are 
limited, despite several companion diagnostic assays by detecting PD-L1 in tumor cells have been introduced into 
clinical practice. Therefore, in this era of precision medicine, there is an urgent need for predictive biomarkers to iden-
tify NSCLC patients likely to benefit from this novel therapy.
Keywords: Immune checkpoint blockade, Non-small cell lung cancer (NSCLC), PD-1, PD-L1, Precision medicine, 
Nivolumab (Opdivo), Pembrolizumab (Keytruda), Atezolizumab (Tecentriq)
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made.
Lung cancer is a leading cause of cancer-related death 
worldwide, and non-small cell lung cancer (NSCLC) 
accounts for about 80–85% of all patients with lung 
cancer. Despite the pathogenesis of NSCLC are well 
researched and a number of novel drugs are being devel-
oped to target a variety of oncogenic drivers, such as epi-
dermal growth factor receptor-tyrosine kinase inhibitors 
(EGFR-TKIs) (e.g. gefitinib, erlotinib, afatinib and osimer-
tinib) and anaplastic lymphoma kinase (ALK) targeted 
agents, (e.g. crizotinib, alectinib, ceritinib and brigatinib), 
the presence of undruggable targets and the development 
of drug resistance limits the efficacy of treatment of tar-
geted therapies for NSCLC. Encouragingly, the success 
of immune checkpoint blockade therapy in NSCLC has 
recently gained widespread recognition, with the scope 
to develop a diverse repertoire of synergistic and precise 
immunotherapeutics, although NSCLC was historically 
thought to be non-immunogenic [1].
An immune checkpoint blockade or inhibitor is 
designed to target inhibitory checkpoint molecules, 
such as programmed cell death protein 1 (PD-1), and 
its ligand programmed cell death protein ligand-1 (PD-
L1) or cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) (Fig.  1) [2]. The promising therapeutic activ-
ity in both squamous and non-squamous carcinomas has 
led US Food and Drug Administration approval for two 
antibodies to PD-1, Nivolumab (Opdivo) (http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm466413.htm) and Pembrolizumab (Keytruda) (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm465444.htm) [3], and one antibody to PD-L1, 
Atezolizumab (Tecentriq) (http://www.fda.gov/drugs/
informationondrugs/approveddrugs/ucm525780.htm) 
[4] for NSCLC treatments with the prescribing infor-
mation as an associated immunohistochemistry (IHC)-
based companion or complementary diagnostic test 
for PD-L1 [5]. However, not all patients with advanced 
NSCLC benefit from these drugs. The response rates to 
these antibodies are only 15–20% in unselected NSCLC 
patients, suggesting there is a necessity to improve the 
response rate by selection of patients. The biomarkers for 
predicting the safety and efficacy of immune checkpoint 
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blockade therapy currently remains lacking in NSCLC, 
which has significantly limited the harness of these 
potential agents as personalized medicine for the disease.
There are two different IHC assays approved for 
examining PD-L1 expression in formalin-fixed paraf-
fin-embedded (FFPE) NSCLC tissue by FDA in Octo-
ber 2015, i.e. PD-L1 IHC 22C3 pharmDx linking to the 
use of pembrolizumab (Keytruda), and PD-L1 IHC 28-8 
pharmDx linking to nivolumab (Opdivo) [3]. Recently, 
Roche also offered the VENTANA PD-L1 (SP142) Assay 
for atezolizumab (Tecentriq) in the assessment of PD-L1 
protein in FFPE urothelial carcinoma and NSCLC tis-
sues [6]. Indeed, results from the KEYNOTE-001 [7], 
CheckMate 057 [8], KEYNOTE-021 [9] and POPLAR 
[10] studies demonstrated that the efficacy of the PD-1/
PD-L1 checkpoint blockades in advanced NSCLC 
patients was correlated with the expression of PD-L1. 
A better survival for pembrolizumab treatment was 
observed in patients with NSCLC who had more than 
50% of PD-L1 positive tumor cells tested by PD-L1 IHC 
22C3 pharmDx. With respect to nivolumab, no ideal 
biomarker has been identified yet, despite the IHC 28-8 
pharmDx assay has been suggested as an accompanying 
diagnostic assay for the use of Opdivo. Indeed, a greater 
than 1% PD-L1-expressing tumor cells determined by 
this assay was associated with enhanced survival from 
nivolumab therapy versus docetaxel in non-squamous 
NSCLC patients [11]. However, it remains an open ques-
tion whether nivolumab can be an alternative for those 
patients with fewer than 50% PD-L1 positive tumor cells 
tested by PD-L1 IHC 22C3 pharmDx, since nivolumab 
monotherapy showed an equivalent efficacy, not inferior 
to docetaxel for PD-L1-negative tumors, but superior 
to docetaxel for PD-L1-positive NSCLC, indicating that 
testing for PD-L1 in non-squamous NSCLC for deci-
sion of nivolumab regimen remains an option. These 
scenarios suggest that the predictability based on PD-L1 
expression may differ between non-squamous NSCLC 
and squamous cell NSCLC [3]. With respect to the VEN-
TANA PD-L1 (SP142) assay, the PD-L1 expression in 
≥50% tumor cells or ≥10% immune cells in NSCLC tis-








































Fig. 1 Schematic representation of immune co-stimulatory and co-inhibitory molecule receptors on T-cells and their ligands among T cells, 
antigen-presenting cells and tumor cells, and targeting strategies and agents of immune checkpoint blockade therapy. T-cell activation or inhibi-
tion induced by different co-stimulatory or co-inhibitory receptors (which are expressed on T-cells) bind to their ligands (which are expressed on 
dendritic cells or tumor cells). BTLA B- and T-lymphocyte attenuator, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, HVEM herpes virus entry 
mediator, MHC major histocompatibility complex, PD-1 programmed cell death 1, PD-L1 programmed cell death ligand-1
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overall survival from atezolizumab (Tecentriq) [6]. Taken 
together, a precise selection of NSCLC patients who are 
most likely to benefit from immune checkpoint block-
ade therapies may maximize the benefit and reduce 
the high cost and unexpected immune-related adverse 
events (irAEs) of these therapies. Therefore, in the era 
of Precision Oncology, there is an unmet need for effec-
tive biomarkers that can predict the safety and efficacy of 
immune checkpoint blockade therapy [1, 11].
Despite PD-L1 expression has been used to identify 
good responders and long-term survivors in several 
clinical trials [12], multiple caveats are emerged in PD-1/
PD-L1 based immune checkpoint blockade therapies 
when the sole PD-L1 expression is used as biomarker. 
Numerous factors, increase the technical difficulty of 
standardization for the interpretation of PD-L1 expres-
sion in clinical settings, including the assays, antibodies 
and cut-offs used, the usage of archival or fresh tissue, 
the heterogeneity of synchronous and metachronous 
tumor specimens. In addition to the PD-L1 expression 
in tumor cells, other genetic and epigenetic factors, such 
as tumor microenvironment/immune effector cells, non-
synonymous mutation burden, and oncogene mutations 
in tumor cells, epithelial-to-mesenchymal phenotypes, 
and even smoking history were also found to be associ-
ated with objective response, durable clinical benefit, and 
progression-free survival (PFS) with immune checkpoint 
blockade therapy [11].
It has been recognized that PD-L1 is an inducible 
and dynamic biomarker subject to changes with tumor 
microenvironment (TME). Apart from being expressed 
in tumor cells, it is also expressed in tumor-infiltrating 
lymphocytes (TILs), in which PD-L1 expression may be 
more relevant to immune checkpoint blockade response 
than its expression in tumor cells, i.e. a PD-1 signal-
ing inhibitor may have no effect on a PD-L1 expressing 
tumor lacking an appropriate immune infiltrate. In this 
regard, Smyth et  al. [5] recently suggested a combina-
tion immunotherapy tailored to the TME based on the 
presence of PD-L1 expression and TILs. A TME pheno-
type with the presence of PD-L1 and TILs may benefit 
the most from PD1/PD-L1 blockade. Conversely, a TME 
phenotype with the absence of PD-L1 and lack of TILs 
may correlate with poor response to checkpoint block-
ades. For those NSCLC patients with a TME phenotype 
of PD-L1 constitutively expressed on tumor cells but 
lacking of TILs, or a phenotype of TME tumors contain-
ing TILs but absence of PD-L1, they will most unlikely 
be benefit from a PD-1/PD-L1 blockade therapy, other 
approaches or checkpoint blockades other than PD1/
PD-L1 axis may be effective [5].
Beyond PD-L1 expression, an increasing interest has 
recently spurred in whether the mutational landscape 
affects responses to immune checkpoint blockade, owing 
to a high mutation rate is seen in NSCLC patients, which 
may strongly correlates with smoking history [13]. Fur-
thermore, both EGFR mutation and ALK fusion can 
activate the PI3K/AKT signaling pathway, which in turn 
induced PD-L1 expression, suggesting a correlation of 
these mutations with anti-PD-1 antibody therapy. Indeed, 
patients with wild-type EGFR/KRAS mutations showed 
a greater benefit from nivolumab in terms of PFS and 
overall survival (OS) in the subgroup analysis of Check-
Mate057 study, while those with wild-type EGFR showed 
a better outcome in terms of OS from pembrolizumab 
compare to patients with EGFR mutations in the sub-
group analysis of KEYNOTE-010 study [11]. In addition, 
NSCLC tumors with a higher non-synonymous muta-
tion load (ultimately neoantigen burden) determined 
by exome sequencing, and low neoantigen intratumoral 
heterogeneity were correlated with significantly higher 
overall response rate (ORR) and durable clinical response 
to immune checkpoint blockade [11, 14]. However, such 
association is not absolute, some patients who carry a 
high mutation load also show non-response, a number 
of patients who harbor a low mutation load respond to 
the therapy [11]. This discordance may be attributed by 
the high degree of intratumoral heterogeneity (ITH) in 
NSCLC tumor, since sequencing using the bulk of tumor 
tissue may not fully capture the spatial complexity of the 
mutational landscape [14]. These findings clearly sug-
gest that the response to immune checkpoint blockades 
is largely depended on the patients’ immune status and 
molecular subtypes. Together with the remarkable molec-
ular diversity in NSCLC, these may support to a person-
alized approach to NSCLC immunotherapy based on the 
patients’ molecular characterization and immune status.
Unlike conventional and targeted cancer treatments, 
monitoring the responses of immune checkpoint block-
ades is a challenge in solid tumors, since there are no 
definitive radiologic criteria to differentiate between true 
progression and pseudo-progression available, although 
multiple nuclear probes serving to label and identify TILs 
are currently being tested in clinical trials [15], and the 
high-resolution PET imaging with therapeutic antibody-
based PD-1/PD-L1 checkpoint tracers are also being 
tested in immunocompetent mice [16]. Intriguingly, 
by monitoring PD-L1 positive circulating tumor cells 
(CTCs) in nivolumab-treated NSCLC patients, Nicolazzo 
et  al. [17] found that the patients with PD-L1(−) CTCs 
all obtained clinical benefit while those with PD-L1(+) 
CTCs all experienced progressive disease, suggesting a 
correlation of the persistence of PD-L1(+) CTCs and 
poor outcome of PD-1 blockade therapy.
With respect to precision medicine in immune check-
point blockade therapy, the central goal is to tailor 
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treatment to a patient’s individual immunological pro-
file of both tumor and immune cells. In addition to test 
PD-L1, a multimodal approach including other immune 
inhibitory and stimulatory markers, TCR clonality, 
and somatic mutational burden may be more ideal pre-
dictors for patient identification and the response to 
therapy in NSCLC. Technically, the implementation of 
high-throughput sequencing analysis and genomic tech-
nologies are rapidly becoming part of standard practice, 
which may ultimately allow a more robust prediction of 
response to immune checkpoint blockade. For instance, 
if NSCLC patients who are identified with a high muta-
tional load but with high degree of ITH and no clonal 
CD8 T cell infiltration by integrated approach, they may 
be represented a subtype that is unlikely to respond to 
immune checkpoint blockades [5]. Therefore, it is plau-
sible to integrate both tumor and immune cell profiling 
with molecular data from the expression of checkpoint 
molecules and mutational burden to create the predictive 
assessments for patient selection, which may lead to an 
improved outcomes from immune checkpoint blockade 
therapy and pave the way for precision medicine to sur-
mount NSCLC using these novel agents.
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